Brief: Immunovant Q2 Net Income USD -109.119 Million
07/11/2024 11:30
Nov 07 (Reuters) - Immunovant Q2 operating expenses USD 115.743 million. * Q2 basic EPS USD -0.74
Recent news on Immunovant
See all newsU.S. STOCKS ON THE MOVE-Tesla, Blue Owl, Ford
Immunovant falls as drug for thyroid eye disease fails late-stage trials
Immunovant falls as eye disease therapy fails in late-stage studies
Immunovant Q3 net loss smaller than expected
Brief: Immunovant Q3 Net Income USD -110.635 Million Vs. IBES Estimate USD -125.1 Million